中国癌症防治杂志2026，Vol.18Issue(4)：403-408,6.DOI:10.27054/j.cnki.ISSN.1674-5671.2026.04.02
《肝细胞癌临床试验设计与研究终点:EASL-AASLD-ILCA联合共识声明》摘译与解读
Translation and interpretation of Trial design and end points in hepatocellular carcinoma:an EASL-AASLD-ILCA consensus statement
摘要
Abstract
On June 10,2026,the European Association for the Study of the Liver,the American Association for the Study of Liver Diseases,and the International Liver Cancer Association,in collaboration with the American Society of Clinical Oncology,released the Trial design and end points in hepatocellular carcinoma:an EASL-AASLD-ILCA consensus statement.Developed using a modified Delphi method,this consensus comprises 102 standardized recommendations across eight major research domains and standardizes hepatocellular carci-noma clinical trial design regarding participant enrollment,endpoint definition,stratification design and control-arm design.In light of the current state of clinical research in China,this paper summarizes,selectively translates,and interprets the key points of this consensus.关键词
肝细胞癌/临床试验/研究终点/专家共识/临床指南Key words
Hepatocellular carcinoma/Clinical trial/Trial end point/Expert consensus/Clinical guideline分类
医药卫生引用本文复制引用
罗雯雯,何颖,马义丽,钟鉴宏..《肝细胞癌临床试验设计与研究终点:EASL-AASLD-ILCA联合共识声明》摘译与解读[J].中国癌症防治杂志,2026,18(4):403-408,6.基金项目
广西重点研发计划项目(桂科AB24010082) （桂科AB24010082）
广西医科大学一流学科创新驱动人才计划基金资助项目(桂医大[2024]16号) （桂医大[2024]16号）
广西学位与研究生教育改革课题(JGY2023073) （JGY2023073）
